Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer

Molecular Cancer Therapeutics

Volumn 7, Issue 8, 2008, Pages 2377-2385

  Duan, Zhenfeng ^a,b   Weinstein, Edward J ^c   Ji, Diana ^c   Ames, Rachel Y ^b   Choy, Edwin ^b   Mankin, Henry ^a   Hornicek, Francis J ^a  

^a Sarcoma Biology Laboratory   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Sigma Aldrich Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PRE MESSENGER RNA PROCESSING FACTOR 4; PROTEIN; PROTEIN SERINE THREONINE KINASE; PUROMYCIN; SHORT HAIRPIN RNA; SURVIVIN; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL LINE; CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENE IDENTIFICATION; GENE REPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; LENTIVIRINAE; MITOSIS; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RNA SPLICING; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; BLOTTING, NORTHERN; DNA PRIMERS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; LENTIVIRUS; OVARIAN NEOPLASMS; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEOPROTEIN, U4-U6 SMALL NUCLEAR; RNA, VIRAL;

EID: 53349099399     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0316     Document Type: Article

References (44)

1. See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 2003;13:701-34.
2. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3:1-19.
3. Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res 2002;22:1933-41.
4. Lamendola DE, Duan Z, Yusuf RZ, Seiden MV. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 2003;63:2200-5.
5. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
6. Barre B, Vigneron A, Perkins N, Roninson IB, Gamelin E, Coqueret O. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007;3:4-11.
7. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res 2007;67:4843-50.
8. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005;55:277-85.
9. Duan Z, Brakora KA, Seiden MV. MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the Taxol- and doxorubicin-resistant phenotype in human cancer cell lines. Gene 2004;340:53-9.
10. Bosher JM, Labouesse M. RNA interference: genetic wand and genetic watchdog. Nat Cell Biol 2000;2:E31-6.
11. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004;3:833-8.
12. Cullen BR. Induction of stable RNA interference in mammalian cells. Gene Ther 2006;13:503-8.
13. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006;124:1283-98.
14. Dann CT. New technology for an old favorite: lentiviral transgenesis and RNAi in rats. Transgenic Res 2007;16:571-80.
15. Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 2007;67:5831-9.
16. Li M, Zhang Z, Hill DL, Wang H, Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007;67:1988-96.
17. Zaffaroni N, Daidone MG. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist Updat 2002;5:65-72.
18. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 1999;5:3445-53.
19. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
20. Montembault E, Dutertre S, Prigent C, Giet R. PRP4 is a spindle assembly checkpoint protein required for MPS1, MAD1, and MAD2 localization to the kinetochores. J Cell Biol 2007;179:601-9.
21. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 2004;5:21-53.
22. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59.
23. Buys TP, Chari R, Lee EH, et al. Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. Genes Chromosomes Cancer 2007;46:1069-79.
24. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85-95.
25. Isonishi S, Hom DK, Thiebaut FB, et al. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 1991;51:5903-9.
26. Miyashita T, Reed JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407-11.
27. Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 2002;17:234-42.
28. Duan Z, Duan Y, Lamendola DE, et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 2003;9:2778-85.
29. Rosenberg GH, Alahari SK, Kaufer NF. prp4 from Schizosaccharomyces pombe, a mutant deficient in pre-mRNA splicing isolated using genes containing artificial introns. Mol Gen Genet 1991;226:305-9.
30. Kiger AA, Baum B, Jones S, et al. A functional genomic analysis of cell morphology using RNA interference. J Biol 2003;2:27.
31. Gross T, Lutzelberger M, Weigmann H, Klingenhoff A, Shenoy S, Kaufer NF. Functional analysis of the fission yeast Prp4 protein kinase involved in pre-mRNA splicing and isolation of a putative mammalian homologue. Nucleic Acids Res 1997;25:1028-35.
32. Miyata Y, Nishida E. Distantly related cousins of MAP kinase: biochemical properties and possible physiological functions. Biochem Biophys Res Commun 1999;266:291-5.
33. Kojima T, Zama T, Wada K, Onogi H, Hagiwara M. Cloning of human PRP4 reveals interaction with Clk1. J Biol Chem 2001;276:32247-56.
34. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
35. Tang-Wai DF, Kajiji S, DiCapua F, de Graaf D, Roninson IB, Gros P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995;34:32-9.
36. Kleinberg L, Florenes VA, Nesland JM, Davidson B. Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions. Am J Clin Pathol 2007;128:389-97.
37. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 2003;16:574-83.
38. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-8.
39. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-8.
40. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9.
41. Kondo S, Kondo Y, Hara H, et al. mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer 1996;74:1263-8.
42. Zink D, Fischer AH, Nickerson JA. Nuclear structure in cancer cells. Nat Rev Cancer 2004;4:677-87.
43. Durfee T, Mancini MA, Jones D, Elledge SJ, Lee WH. The aminoterminal region of the retinoblastoma gene product binds a novel nuclear matrix protein that co-localizes to centers for RNA processing. J Cell Biol 1994;127:609-22.
44. Li Y, Lin AW, Zhang X, Wang Y, Wang X, Goodrich DW. Cancer cells and normal cells differ in their requirements for Thoc1. Cancer Res 2007;67:6657-64.